Literature DB >> 12589161

A short course of cyclosporine immunosuppression inhibits rejection but not tolerance of rat liver allografts.

Wen Hua Huang1, Yiqun Yan, Bastiaan De Boer, G Alex Bishop, Anthony K House.   

Abstract

BACKGROUND: Orthotopic liver transplants in many animal models are spontaneously accepted without requiring immunosuppression. Liver transplant acceptance is associated with early immune activation, and immunosuppressive drugs such as methylprednisolone inhibit acceptance. We investigated whether cyclosporine (CsA) inhibits rat liver transplant acceptance. We also examined the effects of CsA on infiltration and cytokine gene expression.
METHODS: Orthotopic liver transplantation was performed in the PVG donor to Dark Agouti recipient rat strain combination, which accepts the graft (tolerance; TOL), and in the PVG-to-Lewis combination, which rejects the graft in 9 to 16 days (rejection; REJ). CsA (1.5 mg/kg per day subcutaneously) was given to recipients for 5 days, starting from the day of transplantation to day 4 or from day 3 to day 7. In a separate experiment, transplanted livers were collected at days 1, 3, 5, and 7 after transplantation and examined for infiltration by immunohistochemistry and for expression of interleukin (IL)-2, IL-4, IL-10, and interferon-gamma mRNA by quantitative reverse transcriptase-polymerase chain reaction.
RESULTS: Both early and delayed treatment with CsA significantly increased survival in the REJ strain combination, with a median survival time of 81 days and more than 100 days, respectively, compared with 13 days in the untreated group. Neither treatment affected survival of TOL animals, and all TOL groups had a median survival time of more than 100 days. Delayed treatment did not reduce survival; more animals survived for greater than 100 days after delayed treatment, although this did not reach significance ( P=0.08). T-cell infiltrate was inhibited in CsA-treated TOL animals compared with untreated animals at all times after treatment, whereas CD25 cells were only inhibited on day 3. CsA treatment of TOL grafts markedly reduced expression of IL-2, IL-4, and interferon-gamma compared with untreated recipients.
CONCLUSIONS: CsA did not significantly inhibit liver transplant acceptance and allowed some activation of T cells and CD25 expression but almost completely inhibited IL-2 and IL-4, which are required for survival of activated T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589161     DOI: 10.1097/01.TP.0000044360.20396.AB

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Transplant tolerance: models, concepts and facts.

Authors:  Nicola J Monk; Roseanna E G Hargreaves; Elizabeth Simpson; Julian P Dyson; Stipo Jurcevic
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

2.  Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection.

Authors:  Jie-Young Lee; Jung Hwan Kim; Gibong Chae; Bong-Ki Lee; Kwon-Soo Ha; Young-Geun Kwon; Young-Myeong Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

Review 3.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

4.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.